Saniona currently has clinical stage candidates for obesity, metabolic diseases and cocaine addiction and has been able to secure collaborations with top pharmaceutical companies.
Saniona has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Proximagen Ltd., Productos Medix, S.A and Luc Therapeutics, Inc.
Tesomet and Tesofensine are the most advanced programs.
NS2359 NS2359 attenuates the euphoria associated with cocaine use. In a phase I human laboratory interaction study, NS2359 showed no toxicity after 20 or 40 mg of cocaine, but it attenuated the both the rewarding and cardiovascular effects of intravenous cocaine. On the basis of these promising studies, investigators propose a Phase II double-blind clinical trial of NS2359 in cocaine addiction (CA). Saniona is collaborating with TRC on developing NS2359 for cocaine addiction. A clinical proof-of-concept study with NS2359 for treatment of cocaine addiction is currently ongoing and is supported by grants from the Dana Foundation and the Groff Foundation.
Tesofensine has been evaluated in Phase 1 and Phase 2 human clinical studies with the aim of investigating treatment potential with regards to obesity, Alzheimer’s disease and Parkinson’s disease. Tesofensine demonstrated strong weight reducing effects in Phase 2 clinical studies in obese patients. In general, tesofensine has been administered to more than 1,300 patients and is well tolerated.
"The clinical Phase 2b trial (TIPO-1), reported in The Lancet, showed levels of weight loss over a six-month period that were of high clinical relevance and highly competitive to other approaches. Patients lost an average of 12.8 kg on a 1 mg dose, 11.3 kg on a 0.5 mg dose and 6.7 kg on a 0.25 mg dose compared with a 2.2 kg loss in the placebo group"
Saniona is collaborating with Medix on developing tesofensine for obesity in Mexico and Argentina. According to Medix, the current market for prescription medicine for obesity in Mexico is about US$ 250 million. In August 2017, Medix initiated a Phase 3 study for tesofensine in obese Mexican patients. The trial is expected to be completed within two years.
Tesomet is a fix-dosed combination of tesofensine and metoprolol. In 2016, Saniona performed a Phase 2a clinical trial for Tesomet in type 2 diabetes patients. Top line data from this clinical trial was presented in January 2017. The clinical trial achieved a positive outcome on the primary endpoint with a statistically significant reduction in heart rate for patients treated with Tesomet compared to placebo. Furthermore, the key secondary and exploratory endpoints regarding body weight and waist circumference also showed statistically significant reductions compared to placebo.
Tesomet has recently shown positive results in its Phase2a study for type 2 diabetes and the Company is currently conducting a Phase 2a study in patients suffering from Prader-Willi syndrome. Acc. to Datamonitor, it is expected that the type 2 diabetes market will grow from $23.3bn in 2014 to $43bn in 2023.
“We are very excited about the initiation of this important Phase 2a study. https://www.linkedin.com/pulse/sanionas-partner-trc-initiates-phase-2a-study-ns2359-cocaine-thomas Pipeline Product to target - Indication - Market - Status
TRC is world class within clinical trials on drug addiction.
The two principal investigators are
recognized leaders in addiction research. Dr. Berrettini is an
internationally-recognized expert in the
genetics of addiction and Dr. Kampman is a highly respected top
researcher in conducting clinical studies of cocaine addiction"
Tesomet - Type 2 diabetes - 23 billion USD (Clinical phase 2)
Tesomet PWS - Prader-Willi syndrome - 2 billion USD only in USA (Clinical phase 2)
Tesofensine - Obesity - 250 million USD only in Mexiko (Clinical phase 3)
NS2359 - Cocaine addiction - 1,8 billion USD only in USA (Clinical phase 2)
GABA-A α2/α3 program - Neuropathic pain - 6 billion USD (Preclinical research)
Boehringer Ingelheim program - Schizophrenia - 4,8 billion USD (Preclinical research)
IK - Inflammation, IBD - 5,9 billion USD (Preclinical research)
Nicotinic α6 program - Parkinson - 2,8 billion USD (Preclinical research)
Proximagen program - Neurological disorders - No data (Preclinical research)
Luc Therapeutic program - Ataxia - Rare disease (Preclinical research
Current market cap approximately 125 million USD
List of Major Shareholders
Jørgen Drejer 11.4% CEO and founder of Saniona
Thomas Feldthus 9% EVP, CFO and Co-founder
Avanza Pension 5.9%
Leif Andersson 4.6% Board member
Palle Christophersen 3.9% CSO and Co-founder
Claus Brästrup 3.5% Chairman
Nordnet Pensionsförsäkring 3.1%
Janus Schreiber Larsen 2.1% Project Director and Co-founder
Jörgen Philip Kiär Ahring 1.9%
Karin Sandager Nielsen 1.7% Head of in vivo pharmacology